Welcome to our dedicated page for Tevogen Bio news (Ticker: TVGNW), a resource for investors and traders seeking the latest updates and insights on Tevogen Bio stock.
Tevogen Bio Holdings Inc. (TVGNW) is a clinical-stage biotechnology company pioneering AI-driven precision T cell therapies for infectious diseases, cancers, and neurological disorders. This page serves as the definitive source for official company announcements, research breakthroughs, and strategic developments.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and partnership announcements. Our curated collection includes press releases covering therapeutic advancements, financial results, intellectual property updates, and leadership changes.
Key focus areas include Tevogen's innovative use of CD8+ cytotoxic T lymphocytes, developments in its Tevogen.AI platform, and strategic collaborations enhancing its immunotherapy pipeline. The news archive provides chronological tracking of the company's progress in creating accessible off-the-shelf treatments.
Bookmark this page for direct access to verified information about TVGNW's scientific advancements and corporate updates. Check regularly for new developments in precision immunotherapy and AI-enhanced drug discovery.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has filed a Registration Statement on Form S-1, which became effective on August 2, 2024. The company's CEO, Ryan Saadi, clarified that this registration does not involve any new issuance of dilutive securities. Instead, it pertains to the registration of earnout shares and shares underlying outstanding warrants, as well as the resale of existing shares and warrants.
Dr. Saadi expressed confidence in Tevogen's growth strategy and emphasized their commitment to providing affordable and accessible therapies. He noted that the company's recent $50 million financing, completed in July, is expected to fund existing operations into the future. The warrants have an exercise price of $11.50 per share, while the earnout shares require Tevogen's stock to reach a threshold price of $15.00 per share over a specified period to trigger issuance.
Tevogen Bio has released a letter to stockholders highlighting recent achievements and growth plans, including the consideration of a potential share buyback. Their lead product, TVGN 489, a Cytotoxic CD8+ T lymphocyte (CTL) immunotherapy for acute COVID-19 in cancer patients, has shown promising Phase I clinical trial results. Additionally, Tevogen Bio is advancing treatments for virally induced cancers, with candidates TVGN 920, TVGN 960, and TVGN 930. The company has also made significant strides with Tevogen.AI in enhancing drug discovery through predictive modeling. In response to recent stock performance, Tevogen Bio is exploring options such as a share repurchase to enhance shareholder value.
On July 10, 2024, Dr. Neal Flomenberg and Dr. Lori Grosso of Tevogen Bio discussed their genetically unmodified, off-the-shelf T cell technology on Nasdaq’s Live From MarketSite with Kristina Ayanian. The ExacTcell™ platform aims to address cost and patient accessibility challenges in treating cancer, infectious diseases, and neurological disorders. Unlike genetically modified autologous T cells, ExacTcell produced hundreds of doses from a single donor in a successful phase I clinical trial, showing no dose-limiting toxicities. Dr. Flomenberg expressed the goal of making T cell immunotherapy a routine, outpatient treatment. The results were published in Blood Advances, highlighting the potential of Tevogen’s innovative approach.
Ryan Saadi, CEO of Tevogen Bio (Nasdaq: TVGN), congratulates Marc Benioff, CEO of Salesforce, on receiving the Yale Legend in Leadership Award. The award, established 35 years ago, celebrates CEOs who exemplify leadership. Saadi, a Yale alumnus and a member of the Yale School of Public Health Leadership Council, emphasizes the alignment of corporate success with social responsibility. He attended the bi-annual CEO Summit alongside other notable business leaders from companies like Palo Alto Networks, Xerox, Verizon, Bank of America, Disney, General Motors, Coca-Cola, and many more, reflecting a shared commitment to integrating business and social prosperity.
Tevogen Bio, a clinical-stage specialty immunotherapy biotech company, filed a Registration Statement on Form S-1 on June 21, 2024. This filing is aimed at registering previously disclosed shares of common stock and the resale of shares and warrants by existing securityholders. Importantly, it does not involve any newly issued dilutive securities.
The filing includes shares underlying warrants issued in 2021 with an exercise price of $11.50 and earnout shares tied to a stock price threshold of $15.00 per share, previously registered in a Form S-4 filing. This registration statement has not yet been declared effective by the SEC.
Tevogen Bio announced positive Phase I clinical trial results for TVGN 489, an investigational SARS-CoV-2 specific T cell immunotherapy, published in Blood Advances. The study involved 12 high-risk patients receiving TVGN 489 and 18 receiving standard care. Notably, TVGN 489 was well-tolerated, with 88% or greater viral elimination by day 4, and over 99% by day 14. No disease progression or Long COVID was observed in the treatment group. The persistence of donor-derived T-cells was seen through the 6-month follow-up, suggesting potential long-term benefits. Tevogen plans to further test the efficacy and safety of TVGN 489 in later stage trials.
Tevogen Bio (Nasdaq: TVGN), a clinical-stage biotech firm, is pioneering off-the-shelf, genetically unmodified T cell therapies in oncology, neurology, and virology. At the Longwood Spring MIT Conference, Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, discussed the transformative potential of Tevogen's T cell technology. Key highlights include the company's efforts to mainstream T cell therapy, reduce manufacturing costs, and eliminate side effects associated with CAR-T therapies. Mehta emphasized Tevogen's capability to produce hundreds of doses from a single donor and its strategy to develop T cell therapies for large patient populations, including those affected by Long COVID and multiple sclerosis. The company's approach focuses on speed, cost efficiency, and innovative pricing strategies, positioning Tevogen as a model for the industry.
Tevogen Bio Holdings (Nasdaq: TVGN) will join the Russell 3000® Index following the 2024 Russell US Indexes annual reconstitution, effective July 1. This inclusion reflects Tevogen's market capitalization among the 4,000 largest U.S. stocks as of April 30. Membership in the Russell 3000® Index entails automatic inclusion in the Russell 1000® or Russell 2000® Index, enhancing visibility among investment managers. Tevogen Bio focuses on developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology. CEO Dr. Ryan Saadi anticipates this will benefit both patients and investors.
Tevogen Bio (Nasdaq: TVGN) has secured up to $50 million in financing to boost its R&D and clinical development. The deal includes a $36 million line of credit and a potential $14 million private placement. The financing will support the development of TVGN 489 from Tevogen's ExacTcell™ technology platform and enhance its IP portfolio.
Tevogen recently eliminated $94.9 million in liabilities, positioning itself strategically for growth. The line of credit allows monthly draws up to $1 million at a low interest rate, payable in cash or stock. The private placement activates at a $10 per share threshold, discounted by 30%.
CEO Dr. Ryan Saadi emphasized the importance of this financing for expanding R&D and making personalized T cell therapies more accessible.
Tevogen Bio Holdings, a clinical-stage immunotherapy firm (Nasdaq: TVGN), held its inaugural post-public listing social engagement on May 31, 2024. The event, attended by elected officials, first responders, and U.S. Congress members, aimed to discuss the company's innovative business model and treatments using CD8+ cytotoxic T lymphocytes for diseases like cancer and neurological disorders. The gathering included mayors from various NJ towns, U.S. Congressmen Josh Gottheimer and Robert Menendez, and first responders like Matthew Caliente and Robert Ferreiro. CEO Dr. Ryan Saadi emphasized the societal value of Tevogen's business model and thanked attendees, particularly the patients who shared their experiences.